Fischer Medical Ventures Reports 123% YoY Surge in Q2 FY26 Income; Share Price in Focus

Fischer Medical Ventures Limited (formerly Fischer Chemic Limited) has reported a remarkable 123% year-on-year growth in total income for Q2 FY2025-26, reflecting its growing presence in India’s rapidly expanding MedTech industry. The company continues to strengthen its leadership in advanced diagnostics, AI-powered healthcare, and medical imaging solutions.

Fischer Medical Ventures Q2 FY26 Earnings Results

For Q2 FY26, Fischer Medical Ventures recorded a total income of ₹88.79 crore, up from ₹39.88 crore in Q2 FY25, representing 122.64% growth. EBITDA jumped to ₹18.74 crore from ₹0.72 crore, marking a 2,511.72% rise, while EBITDA margin expanded sharply to 21.10% from 1.80%. Net profit rose to ₹13.96 crore from ₹0.29 crore, a massive 4,659.63% increase. 

Diluted EPS stood at ₹2.11, compared to ₹0.05 in Q2 FY25. For H1 FY26, total income reached ₹119.70 crore, up 135.90% YoY, with net profit rising to ₹18.97 crore. The company’s margin improvements highlight strong operational efficiency and product scalability.

Strategic Global Expansion and Partnerships

Fischer Medical Ventures has expanded its international presence with the acquisition of a landmark mixed-use property in Malaysia to develop an Integrated Regional Healthcare Hub. 

In Indonesia, it entered a public–private partnership with the City of Jember to deploy AI-powered portable X-ray systems supporting the “TB Free Jember by 2026” initiative, valued at about US$10 million. The company also secured full innovation licensing in Indonesia, enabling participation in the government’s End-TB Handheld X-ray tender.

Read More:Raymond Lifestyle Q2 FY26 Earnings Results Show Strong Domestic Growth Amid Global Headwinds!

Technological and Clinical Milestones

Domestically, Fischer launched high-resolution Open MRI at Sunray Scans, Chennai, and installed PICA 0.35T Open MRI at STNM Hospital, Sikkim. Its AI partner, NYB.AI, won 1st prize at the SuperAI Genesis Global Competition for its AI-driven drug discovery platform. 

The company also achieved regulatory progress for its SpinCare® technology, completing Phase 1 MDR/MDD audit and preparing for an FDA filing by Q4 FY26. Clinical trials at Stanford confirmed SpinCare’s safety and effectiveness in paediatric burns.

Fischer Medical Ventures Share Price Performance

On October 30, 2025, Fischer Medical Ventures share price opened at ₹117.00 on NSE, above the previous close of ₹115.35. During the day, it surged to ₹118.50 and dipped to ₹116.11. The stock is trading at ₹117.31 as of 9:41 AM. The stock registered a moderate gain of 1.70%.

Over the past week, it has moved up by 12.61%, over the past month, it has moved up by 5.68%, and over the past 3 months, it has moved up by 21.73%.

Conclusion

With 123% YoY growth in Q2 FY26 income and over 4,600% rise in profit, Fischer Medical Ventures continues to scale rapidly in India’s MedTech and diagnostics sector. Strategic acquisitions, AI-driven innovations, and Southeast Asian expansion underline its strong growth trajectory and leadership in next-generation healthcare technologies.

Disclaimer:This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.